Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 3, 2000, Pages 281-284

  Schachschal, Guido ^a   Lochs, H ^a   Plauth, M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Doxorubicin; Hepatocellular carcinoma; Tamoxifen

Indexed keywords

DOXORUBICIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0034107138     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012030-00004     Document Type: Article

References (17)

1. 1 Groupe d'Etude et de Traitement du Carcinoma Hépatocellulaire. A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261.
2. 2 Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and further directions. Cancer Treat Rev 1988; 15:1-31.
3. 3 Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8:117-136.
4. 4 Lai Ch-L, Wu P-Ch, Chan GCh-B, Lok AS-F, Lin H-J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer 1988; 62:479-483.
5. 5 Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994; 26:66-68.
6. 6 Francavilla A, Polimeno L, DiLeo A, Barone M, Ove P, Coetzee M, et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology 1989; 9:614-620.
7. 7 Jiang S-Y, Shyu R-Y, Yeh M-Y, Jordan V-C. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 1995; 23:712-719.
8. 8 Cheng AL, Yeh KH, Luo YL, Chuang SE, Chen DS. Synergistic effect of doxorubicin and tamoxifen in the treatment of hepatocellular carcinoma: in vitro and pilot clinical studies [Abstract]. Proc Am Assoc Cancer Res 1995; 36:347A.
9. 9 Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987; 71:1213-1216.
10. 10 Cheng AL, Chen YC, Yeh KH, Chuang SE, Chen BR, Chen DS. Chronic oral etoposid and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996; 77:872-877.
11. 11 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni NC, Williams R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
12. 12 International Union Against Cancer. TNM Classification of Malignant Tumours, 4th fully revised edition. Geneva: International Union Against Cancer; 1987.
13. 13 World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization; 1997.
14. 14 Farinati F, De Maria N, Fornasiero A, Salvagnini M, Fagiuoli S, Chiaramonte M, et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992; 37:659-662.
15. 15 Cerezo FJM, Tomás A, Donoso L, Enriques J, Guamer C, Balanzó J, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20:702-706.
16. 16 Castells A, Bruix J, Bru̇ C, Ayuso C, Roca M, Boix L, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 105:917-922.
17. 17 Pignata S, Daniele B, Gallo C, De Vivo R, Monfardini S, Perrone F. Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit? Eur J Cancer 1998; 34:25-32.